Stock TCON TRACON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.79 USD -5.29% Intraday chart for TRACON Pharmaceuticals, Inc. -15.17% -48.89%
Apr. 03 TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned CI
Mar. 06 HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TRACON Pharmaceuticals Announces Reverse Stock Split
AQ
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
AQ
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
CI
HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating
MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tracon: Q4 Earnings Snapshot
AQ
Transcript : TRACON Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M
MT
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
AQ
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
AQ
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
AQ
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
CI
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump
MT
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment
CI
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
AQ
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks
MT
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments
MT
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading
MT
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TCON Stock
  4. News TRACON Pharmaceuticals, Inc.